Visceral leishmaniasis - Current therapeutic modalities

Indian Journal of Medical Research

Volumn 123, Issue 3, 2006, Pages 345-352

  Sundar, Shyam ^a,c   Chatterjee, Mitali ^b  

^a BANARAS HINDU UNIVERSITY   (India)

^b INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

^c NONE   (India)

Author keywords

Antileishmanial drugs; Chemotherapy; Immunomodulators; Visceral leishmaniasis

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTIMONY DERIVATIVE; ANTIMONY GLUCONATE; EDELFOSINE; FLUCONAZOLE; IMMUNOMODULATING AGENT; ITRACONAZOLE; KETOCONAZOLE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PENTAMIDINE ISETHIONATE; PYRROLE DERIVATIVE; RECOMBINANT INTERFERON; SITAMAQUINE; STIBOGLUCONATE SODIUM;

ANTIPROTOZOAL ACTIVITY; CARDIOTOXICITY; CHEMOTHERAPY; CHILL; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DRUG APPROVAL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; INDIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY DYSFUNCTION; METHEMOGLOBINEMIA; MONITORING; MYOCARDITIS; NEPHROTOXICITY; NONHUMAN; RELAPSE; REVIEW; RIGOR; SINGLE DRUG DOSE; SUPERINFECTION; THROMBOPHLEBITIS; VISCERAL LEISHMANIASIS; VOMITING;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; ANTIMONY SODIUM GLUCONATE; ANTINEOPLASTIC AGENTS; ANTIPROTOZOAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; LEISHMANIA; LEISHMANIASIS, VISCERAL; PENTAMIDINE;

EID: 33745224305     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the indian epidemic. Clin Infect Dis 2000; 31: 1104-7.
2. Thakur CP, Narayan S, Ranjan A. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian J Med Res 2004; 120: 166-72.
3. Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, et al. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 1999; 180: 564-7.
4. Berman JD, Waddell D, Hanson BD. Biochemical mechanisms of the antileishmanial activity of sodium stibogluconate. Antimicrob Agents Chemother 1985; 27: 916-20.
5. Berman JD, Gallalee JV, Best JM. Sodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid beta-oxidation in Leishmania mexicana amastigotes. Biochem Pharmacol 1987; 36: 197-201.
6. Berman JD, Edwards N, King M, Grogl M. Biochemistry of Pentostam resistant Leishmania. Am J Trop Med Hyg 1989; 40: 159-64.
7. Chakraborty AK, Majumder HK. Mode of action of pentavalent antimonials: specific inhibition of type I DNA topoisomerase of Leishmania donovani. Biochem Biophys Res Commun 1988; 152: 605-11.
8. Wyllie S, Cunningham ML, Fairlamb AH. Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem 2004; 279: 39925-32.
9. Veeken H, Ritmeijer K, Seaman J, Davidson R. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health 2000; 5: 312-7.
10. Sundar S, Sinha PR, Agarwal NK, Srivastava R, Rainey PM, Berman JD, et al. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am J Trop Med Hyg 1998; 59: 139-43.
11. Rijal S, Chappuis F, Singh R, Boelaert M, Loutan L, Koirala S. Sodium stibogluconate cardiotoxicity and safety of generics. Trans R Soc Trop Med Hyg 2003; 97: 597-8.
12. Thakur CP, Kumar K. Efficacy of prolonged therapy with stibogluconate in post kala-azar dermal leishmaniasis. Indian J Med Res 1990; 91: 144-8.
13. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 2003; 3: 87-98.
14. Bray PG, Barrett MP, Ward SA, de Koning HP. Pentamidine uptake and resistance in pathogenic protozoa: past, present and future. Trends Parasitol 2003; 19: 232-9.
15. Jha TK. Evaluation of diamidine compound (pentamidine isethionate) in the treatment of resistant cases of kala-azar occurring in North Bihar, India. Trans R Soc Trop Med Hyg 1983; 77: 167-70.
16. Jha SN, Singh NK, Jha TK. Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial. J Assoc Physicians India 1991; 39: 314-6.
17. Ramos H, Valdivieso E, Gamargo M, Dagger F. Cohen BE. Amphotericin B kills unicellular Leishmania by forming aqueous pores permeable to small cations and anions. J Membr Biol 1996; 152: 65-75.
18. Sundar S, Rai M. Advances in the treatment of leishmaniasis. Curr Opin Infect Dis 2002; 15: 593-8.
19. Meyerhoff A. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis. Clin Infect Dis 1999; 28: 42-8; discussion 49-51.
20. Murray HW. Treatment of visceral leishmaniasis in 2004. Am J Trop Med Hyg 2004; 71: 787-94.
21. Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg 1996; 90: 319-22.
22. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 2002; 66: 143-6.
23. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003; 37: 800-4.
24. Sundar S, Murray HW. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. J Infect Dis 1996; 173: 762-5.
25. Sundar S, Goyal AK, More DK, Singh MK, Murray HW. Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex. Ann Trop Med Parasitol 1998; 92: 755-64.
26. Dietze R, Milan EP, Berman JD, Grogl M, Falqueto A, Feitosa TF, et al. Treatment of Brazilian kala-azar with a short course of Amphocil (amphotericin B cholesterol dispersion). Clin Infect Dis 1993; 17: 981-6.
27. Dietze R, Fagundes SM, Brito EF, Milan EP, Feitosa TF, Suassuna FA, et al. Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days. Trans R Soc Trop Med Hyg 1995; 89: 309-11.
28. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 2004; 38: 377-83.
29. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 2001; 323: 419-22.
30. Syriopoulou V, Daikos GL, Theodoridou M, Pavlopoulau I, Manolaki AG, Sereti E, et al. Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis. Clin Infect Dis 2003; 36: 560-6.
31. Verweij J, Planting A, van der Burg M, Stoter G. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours. J Cancer Res Clin Oncol 1992; 118: 606-8.
32. Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998; 352: 1821-3.
33. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341: 1795-800.
34. Sundar S, Gupta LB, Makharia MK, Singh MK, Voss A, Rosenkaimer F, et al. Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 1999; 93: 589-97.
35. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347: 1739-46.
36. Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr Infect Dis J 2003; 22: 434-8.
37. Bhattacharya SK, Jha TK, Sundar S, Thakur CP, Engel J, Sindermann H, et al. Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis 2004; 38: 217-21.
38. Maly K, Uberall F, Schubert C, Kindler E, Stekar J, Brachwitz H, et al. Interference of new alkylphospholipid analogues with mitogenic signal transduction. Anticancer Drug Des 1995; 10: 411-25.
39. Verma NK, Dey CS. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob Agents Chemother 2004; 48: 3010-5.
40. Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance. Trop Med Int Health 2001; 6: 928-34.
41. Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 1990; 84: 221-5.
42. Thakur CP, Olliaro P, Gothoskar S, Bhownick S, Choudhury BK, Prasad S, et al. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin). antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg 1992; 86: 615-6.
43. Thakur CP, Bhowmick S, Dolfi L, Olliaro P. Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose-finding clinical trial. Trans R Soc Trop Med Hyg 1995; 89: 219-23.
44. Jha TK, Olliaro P, Thakur CP, Kanyok TP, Singhania BL, Singh IJ, et al. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 1998; 316: 1200-5.
45. Seaman J, Pryce D, Sondorp HE, Moody A, Bryceson AD, Davidson RN. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis 1993; 168: 715-20.
46. Thakur CP, Kanyok TP, Pandey AK, Sinha GP, Zaniewski AE, Houlihan HH, et al. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 2000; 94: 429-31.
47. Yamabe S. Inhibitory effects of aminoglycoside antibiotics on reduction of cytochrome c from Candida krusei. Chemotherapy 1980; 26: 28-35.
48. Maarouf M, Lawrence F, Croft SL, Robert-Gero M. Ribosomes of Leishmania are a target for the aminoglycosides. Parasitol Res 1995; 81: 421-5.
49. Maarouf M, de Kouchkovsky Y, Brown S, Petit PX, Robert-Gero M. In vivo interference of paromomycin with mitochondrial activity of Leishmania. Exp Cell Res 1997; 232: 339-48.
50. Berman JD. Activity of imidazoles against Leishmania tropica in human macrophage cultures. Am J Trop Med Hyg 1981; 30: 566-9.
51. Urbina JA. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology 1997; 114: S91-9.
52. Berman JD, Goad LJ, Beach DH, Holz GG Jr. Effects of ketoconazole on sterol biosynthesis by Leishmania mexicana mexicana amastigotes in murine macrophage tumor cells. Mol Biochem Parasitol 1986; 20: 85-92.
53. Beach DH, Goad LJ, Holz GG Jr. Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. Mol Biochem Parasitol 1988; 31: 149-62.
54. Hart DT, Lauwers WJ, Willemsens G, Vanden Bossche H, Opperdoes FR. Perturbation of sterol biosynthesis by itraconazole and ketoconazole in Leishmania mexicana infected macrophages. Mol Biochem Parasitol 1989; 33: 123-34.
55. Wali JP, Aggarwal P, Gupta U, Saluja S, Singh S. Ketoconazole in treatment of visceral leishmaniasis. Lancet 1990; 336: 810-1.
56. Wali JP, Aggarwal P, Nandy A, Singh S, Addy M, Guha SK, et al. Efficacy of sodium antimony gluconate and ketoconazole in the treatment of kala-azar-a comparative study. J Commun Dis 1997; 29: 73-83.
57. Sundar S, Kumar K, Singh VP. Ketoconazole in visceral leishmaniasis. Lancet 1990; 336: 1582-3.
58. Jha TK, Singh NK, Jha S. Ketoconazole in antimonial unresponsive cases of Kala-azar. J Assoc Physicians India 1995; 43: 347.
59. Sundar S, Singh VP, Agarwal NK, Gibbs DL, Murray HW. Treatment of kala-azar with oral fluconazole. Lancet 1996; 348: 614.
60. Sundar S, Kumar P, Makharia M, Goyal A, Rogers M, Gibbs D, et al. Atovaquone alone or with fluconazole as oral therapy for Indian kala-azar. Clin Infect Dis 1998; 27: 215-6.
61. Awasthi A, Mathur RK, Saha B. Immune response to Leishmania infection. Indian J Med Res 2004; 119: 238-58.
62. Sacks D, Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002; 2: 845-58.
63. Badaro R, Falcoff E, Badaro FS, Carvalho EM, Pedral-Sampaio D, Barral A, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med 1990; 322: 16-21.
64. Sundar S, Singh VP, Sharma S, Makharia MK, Murray HW. Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. J Infect Dis 1997; 176: 1117-9.
65. Chapman WL Jr, Hanson WL, Waits VB, Kinnamon KE. Antileishmanial activity of selected compounds in dogs experimentally infected with Leishmania donovani. Rev Inst Med Trop Sao Paulo 1979; 21: 189-93.
66. White MR, Chapman WL Jr, Hanson WL. Chemotherapy of experimental visceral leishmaniasis in the opossum. J Parasitol 1989; 75: 176-8.
67. Sherwood JA, Gachihi GS, Muigai RK, Skillman DR, Mlugo M, Rashid JR, et al. Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin Infect Dis 1994; 19: 1034-9.
68. Dietze R, Carvalho SFG, Valli IC, Berman J, Brewer T, Mlhous W, et al. Phase 2 trial of WR 6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am J Trop Med Hyg 2001; 65: 685-9.